Understanding MADD over time
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people with MADD over time to understand how the condition changes, with the goal of improving future care and treatment. It does not test a new medication – it collects information through visits and tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of MADD from a doctor.
- You or your legal guardian can sign a form saying you agree to be in the study.
- You do not have any other major health conditions unrelated to MADD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called sodium phenylbutyrate (ACER-001) to see if it helps people with MCADD, a genetic condition that affects how your body breaks down fats. If you have MCADD and the common gene change, you might be able to join.
This trial tests how medium-chain fatty acids (a type of fat found in coconut oil) affect metabolism in people with MCADD, a genetic condition that affects fat breakdown, compared to healthy people. The results may help guide dietary advice for those with MCADD.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study tracks how SSADH deficiency (a genetic condition) affects health over time. There is no new drug being tested; instead, researchers collect medical history and perform certain optional scans/tests that can help describe disease patterns and future treatment needs.
This study follows people with fatty liver disease over many years to understand how the condition progresses and what health outcomes they have. By joining, you help researchers learn more about the long-term effects of liver disease.
This study tests an investigational drug called ALN-CIDEB for people with MASH, a liver condition linked to metabolic issues, that has caused moderate liver scarring. The goal is to see if the drug can reduce liver damage and improve liver health.
Hear when a new Multiple Acyl-CoA Dehydrogenase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.